CRISPR Therapeutics vs Heartflow

CRISPR Therapeutics (CRSP), health care, and Heartflow (HTFL), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Heartflow is worth $4.1B on the stock market and CRISPR Therapeutics $3.9B: Heartflow is valued at 6% more. CRISPR Therapeutics's operating margin in its latest fiscal year was -18934% and Heartflow's -36.4%. Over the past year CRISPR Therapeutics's share price has moved -24.5% and Heartflow's +71.6%.

Key facts

CRISPR Therapeutics market value
$3.9B
Heartflow market value
$4.1B
Heartflow P/E
70.3
CRISPR Therapeutics revenue
$3.5MFY to 2025-12-31
Heartflow revenue
$176MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

CRISPR Therapeutics vs Heartflow: every measure side by side
Measure CRISPR Therapeutics Heartflow
SectorHealth CareHealth Care
Country Switzerland United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$3.9Blower$4.1Bhigher
Revenue$3.5Mlower$176Mhigher
Earnings-$581.6Mlower-$116.8Mhigher
Employees—843
Total assets$2.3Bhigher$359.5Mlower
Valuation
P/E—70.3
P/S1110higher23.5lower
P/B—14.6
Dividend yield—0.00%
Profitability
Operating margin-18934%lower-36.4%higher
Balance sheet
Net assets$1.9Bhigher$300.6Mlower
Total liabilities$343.4Mhigher$58.8Mlower
Total debt——
Cash on hand$347.6Mhigher$44.8Mlower
Price change
Today-0.54%lower+0.45%higher
1 year-24.5%lower+71.6%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

CRISPR Therapeutics only (1)

Heartflow only (3)

Percentages are each holding's share of that investor's reported portfolio. Who owns CRSP · Who owns HTFL

Further comparisons

Learn

Questions and answers

Which is bigger, CRISPR Therapeutics or Heartflow?

By market value, Heartflow is the larger: $4.1B against $3.9B for CRISPR Therapeutics. By revenue in its latest fiscal year, Heartflow is the larger: $176M against $3.5M for CRISPR Therapeutics.

Which has the higher operating margin?

Heartflow: -36.4%, against -18934% for CRISPR Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both CRISPR Therapeutics and Heartflow?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds CRISPR Therapeutics and 3 hold Heartflow.

Cite this page

Funkfolio, “CRISPR Therapeutics vs Heartflow”, data as of 18 November 2026. https://funkfolio.com/compare/crsp-vs-htfl

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.